Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: A feasibility study

被引:0
|
作者
Coley, HM
Sargent, JM [1 ]
Williamson, CJ
Titley, J
Scheper, RJ
Gregson, SE
Elgie, AW
Lewandowicz, GM
Taylor, CG
机构
[1] Pembury Hosp, Pembury TN2 4QJ, Kent, England
[2] Inst Canc Res, CRC, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England
[3] Free Univ Amsterdam Hosp, Dept Pathol, NL-1007 MB Amsterdam, Netherlands
关键词
MDR; ovarian cancer; P-glycoprotein; chemosensitivity; drug modulation;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This in vitro feasibility study has assessed a number of techniques and their applicability when looking at the role of multidrug resistance (MDR) in solid tumours. Fresh tumour material was obtained from 34 patients, (11 previously treated, 23 untreated) with ovarian adenocarcinoma. Doxorubicin sensitivity was measured using the MTT assay +/- the cyclosporins, Pgp expression was assessed by immunocytochemistry with the MRK-16 MoAb and flow cytometry was used to assess intracellular drug accumulation +/- PSC 833. 85% of samples showed some evidence of modest chemosensitisation by the cyclosporins (median 1.74-fold). We saw a marked variation in the number of Pgp positive cells between patients (1-87%, median 31%). 63% of samples tested showed an enhancement of DNR accumulation in the presence of PSC 833, with a median increase of 7% (sample range 0-29%). The present study highlights some of the technical difficulties encountered when working with fresh tumour material ex vivo. We conclude that screening of patients for their suitability to enter clinical trials incorporating MDR modulating agents is technically demanding, but feasible.
引用
收藏
页码:69 / 74
页数:6
相关论文
共 50 条
  • [31] Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma
    Eisenhauer, Eric L.
    Sonoda, Yukio
    Levine, Douglas A.
    Abu-Rustum, Nadeem R.
    Gemignani, Mary L.
    Sabbatini, Paul J.
    Barakat, Richard R.
    Chi, Dennis S.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2008, 198 (02) : 213.e1 - 213.e7
  • [32] Prognostic Significance of Hemoglobin Levels in Patients with Primary Epithelial Ovarian Carcinoma Undergoing Platinum-based Chemotherapy
    Pongsanon, Khemmawan
    Benjapibal, Mongkol
    Ruengkhachorn, Irene
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (01) : 131 - 136
  • [33] Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study
    Ong, Jue-Sheng
    Hwang, Liang-Dar
    Cuellar-Partida, Gabriel
    Martin, Nicholas G.
    Chenevix-Trench, Georgia
    Quinn, Michael C. J.
    Cornelis, Marilyn C.
    Gharahkhani, Puya
    Webb, Penelope M.
    MacGregor, Stuart
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2018, 47 (02) : 450 - 459
  • [34] A phase I study of weekly topotecan and paclitaxel in previously treated epithelial ovarian carcinoma patients
    Homesley, H
    Benigno, B
    Williams, J
    Vaccarello, L
    GYNECOLOGIC ONCOLOGY, 2002, 87 (02) : 171 - 177
  • [35] The feasibility of using short-term cultures of ovarian cancer cells for use as autologous tumor cell vaccines as adjuvant treatment of advanced ovarian cancer
    Dillman, RO
    Nayak, SK
    Brown, JV
    Mahdavi, K
    Beutel, LD
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1999, 14 (06) : 443 - 449
  • [36] A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study
    Morgan, Mark A.
    Sill, Michael W.
    Fujiwara, Keiichi
    Greer, Benjamin
    Rubin, Stephen C.
    DeGeest, Koen
    Yamada, S. Diane
    Waggoner, Steven
    Coleman, Robert L.
    Walker, Joan L.
    Mannel, Robert S.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : 264 - 268
  • [37] Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A gynecologic oncology group study
    Dizon, Don S.
    Sill, Michael W.
    Gould, Natalie
    Rubin, Stephen C.
    Yamada, S. Diane
    DeBernardo, Robert L.
    Mannel, Robert S.
    Eisenhauer, Eric L.
    Duska, Linda R.
    Fracasso, Paula M.
    GYNECOLOGIC ONCOLOGY, 2011, 123 (02) : 182 - 186
  • [38] Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma
    Muntz, Howard G.
    Malpass, Thomas W.
    McGonigle, Kathryn F.
    Robertson, Mandy D.
    Weiden, Paul L.
    CANCER, 2008, 113 (03) : 490 - 496
  • [39] Establishment of Primary Cell Culture From Ascitic Fluid and Solid Tumor Obtained From Epithelial Ovarian Carcinoma Patients
    Kar, Rajarshi
    Chawla, Diwesh
    Gupta, Bindiya
    Mehndiratta, Mohit
    Wadhwa, Neelam
    Agarwal, Rachna
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (09) : 2000 - 2005
  • [40] Successful reconstitution of high-grade serous ovarian carcinoma in vivo from primary fallopian tube epithelial cells
    Nakamura, Kohei
    Nakayama, Kentaro
    Kiyono, Tohru
    Sanuki, Kaori
    Yamashita, Hitomi
    Ishikawa, Masako
    Kyo, Satoru
    CANCER SCIENCE, 2018, 109 : 309 - 309